Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Investigating the association between physicians self-efficacy regarding communication skills and risk of "burnout".
Messerotti A, Banchelli F, Ferrari S, Barbieri E, Bettelli F, Bandieri E, Giusti D, Catellani H, Borelli E, Colaci E, Pioli V, Morselli M, Forghieri F, Galeazzi GM, Marasca R, Bigi S, D'Amico R, Martin P, Efficace F, Luppi M, Potenza L. Messerotti A, et al. Among authors: barbieri e. Health Qual Life Outcomes. 2020 Aug 6;18(1):271. doi: 10.1186/s12955-020-01504-y. Health Qual Life Outcomes. 2020. PMID: 32762755 Free PMC article.
Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
Galassi L, Colasante C, Bettelli F, Gilioli A, Pioli V, Giusti D, Morselli M, Paolini A, Nasillo V, Lusenti B, Colaci E, Donatelli F, Catellani H, Pozzi S, Barbieri E, Del Rosso MN, Barozzi P, Lagreca I, Martinelli S, Maffei R, Riva G, Tenedini E, Roncati L, Marasca R, Potenza L, Comoli P, Trenti T, Manfredini R, Tagliafico E, Luppi M, Forghieri F. Galassi L, et al. Among authors: barbieri e. Leuk Res. 2021 Dec;111:106747. doi: 10.1016/j.leukres.2021.106747. Epub 2021 Nov 9. Leuk Res. 2021. PMID: 34781054 No abstract available.
Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.
Barbieri E, Maccaferri M, Leonardi G, Giacobbi F, Corradini G, Lagreca I, Barozzi P, Potenza L, Marasca R, Luppi M. Barbieri E, et al. Ann Hematol. 2022 Dec;101(12):2777-2779. doi: 10.1007/s00277-022-04978-6. Epub 2022 Sep 15. Ann Hematol. 2022. PMID: 36104630 Free PMC article. No abstract available.
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
Cordella S, Parisotto A, Bettelli F, Morselli M, Barbieri E, Pozzi S, Aquilino A, Repaci G, Cuoghi A, Bresciani P, Messerotti A, Colasante C, Gilioli A, Pioli V, Giusti D, Colaci E, Cassanelli L, Ceccherelli G, Bevini M, Malavolti R, Venturelli D, Paolini A, Martinelli S, Maffei R, Riva G, Nasillo V, Trenti T, Comoli P, Tagliafico E, Manfredini R, Barozzi P, Potenza L, Marasca R, Luppi M, Forghieri F. Cordella S, et al. Among authors: barbieri e. Ann Hematol. 2023 Jan;102(1):213-217. doi: 10.1007/s00277-022-05013-4. Epub 2022 Oct 20. Ann Hematol. 2023. PMID: 36261597 No abstract available.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Vigna E, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pettine L, Vincelli ID, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Reddiconto G, Maroccia A, Franceschini L, Bertuglia G, Nappi D, Barbieri E, Gamberi B, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P, Gentile M. Martino EA, et al. Among authors: barbieri e. Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290. Hematol Oncol. 2024. PMID: 38818978
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, Peano S, Franceschetto A, Monaco L, Barbieri E, Ladetto M, Musuraca G, Tosi P, Bianchi B, Bolis SAM, Pavone V, Chiarenza A, Arcari A, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Roti G, Galimberti S, Gini G, Falcinelli F, Vitolo U, Usai SV, Stefani PM, Ibatici A, Liberati AM, Pennese E, Perrone T, Versari A, Luminari S; Fondazione Italiana Linfomi (FIL). Guerra L, et al. Among authors: barbieri e. Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 May 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120 Clinical Trial.
722 results